Effect of Unani drug Majoon chobchini and Leech therapy in patients of Psoriatic arthritis

Therapeutic evaluation of Majoon Chobchini and Leech Therapy in mild to moderate cases of Psoriatic Arthritis - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070050

Enrollment

Registered

2024-07-05

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M148- Arthropathies in other specified diseases classified elsewhere

Interventions

Intervention1: Leech Therapy and Majoon Chobchini: Patients will ask to take Majoon Chobchini 1 teaspoon twice a day along with application of 4-6 leeches on affected joint, weekly for 8 weeks and the

Eligibility

Inclusion criteria

Inclusion criteria: 1. Psoriatic lesion along with arthritis 2. Evidence of psoriasis (any of three) a. Current: Psoriatic skin or scalp disease present, as judged by a dermatologist or rheumatologist. b. Personal history: May be obtained from the patient, family doctor, dermatologist, or rheumatologist. c. Family history: In a first or second degree relative, according to the patient report. 3. Seronegative RA Factor 4. Dactylitis a. Current: swelling of an entire digit. 5. Plain X-rays of the affected Joints (Pencil in cup deformity, juxta articular new bone formation and destruction). 6. USG of affected Joints (Tendinitis/ Enthemopathy). (Diagnostic criteria - CASPAR Criteria 2006) 7. Patients Between the age group 30-60 years of either sex. 8. Patients on any concomitant therapy of Unani medicine for the problem of psoriasis. 9. Those patients agreed and signed the written consent proforma.

Exclusion criteria

Exclusion criteria: 1. Doubtful cases of Psoriatic arthritis 2. Psoriatic arthritis with systemic illnesses like Diabetes mellitus, Chronic Liver Disease & Chronic Kidney Diseases 3. Psoriatic arthritis with secondary infections 4. Immunocompromised patients 5. Below the age of 30 years and above the 60 years.

Design outcomes

Primary

Measure	Time frame
Improvement in joint swelling and pain (Synovitis) Improvement in mobility of joints Improvement in USG finding particularly size joint space, bony erosion, inflammation of entheses (Enthesopathy).Timepoint: one year	—

Secondary

Measure	Time frame
Improvement or check the destruction in X-Ray finding. VAS IL-17 and IL-23 Anti-LL-37 TNF-alphaTimepoint: one year	—

Countries

India

Contacts

Public ContactMohammad Shoaib

Department of Ilaj Bit Tadbeer, Faculty of Unani Medicine, AMU, Aligarh

drmshoaib77@gmail.com9411491568

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026